A Phase IIa Clinical Trial of Berubicin for the Treatment of Glioblastoma (GBM)
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2018
At a glance
- Drugs Berubicin (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors CNS Pharmaceuticals
- 25 Apr 2018 As per CNS Pharmaceuticals website, the company expects to commence this phase 2a trial in 2018.
- 25 Apr 2018 New trial record
- 18 Apr 2018 According to a CNS Pharmaceuticals media release, this trial is expected to be funded in part by an equity crowdfunding campaign.